Aimovig Priced ‘Well Below’ Part D Specialty Threshold To Avoid Coinsurance
Executive Summary
Amgen-Novartis pricing strategy seeks to ensure patients are subject to flat copays rather than coinsurance, which is calculated as a percentage of drug's list price.
You may also be interested in...
Trump Expecting Rx Price Reduction Announcements In Two Weeks
Look for Administration to take credit for any positive pricing news as President says several firms will 'announce voluntary massive drops in prices.'
Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price
Amgen and Novartis won the first US FDA approval for a CGRP inhibitor in the prevention of migraine headaches. The companies aim to quickly capture a big share of what they estimate to be an 8m-patient market in the US with a $6,900 per year price tag.
New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests
Draft cost effectiveness report released by the Institute for Clinical and Economic Review uses $8,500 annual cost for Aimovig and fremanezumab as a "placeholder" price.